Literature DB >> 21085976

Long-term damage to the ENT system in Wegener's granulomatosis.

Marcos Martinez Del Pero1, Michael Walsh, Raashid Luqmani, Oliver Flossmann, Chetan Mukhtyar, Piyush Jani, Niels Rasmussen, David Jayne.   

Abstract

The objectives of the study are to describe long-term ENT damage and assess risk factors in patients with newly diagnosed and treated Wegener's granulomatosis (WG) using the vasculitis damage index (VDI). Data from four randomised controlled trials carried out by the European Vasculitis Study Group was used. Patients newly diagnosed with WG with complete data at 5 years were included. Patients enrolled into the trials without 5-year data were excluded. Total and ENT VDI scores were recorded at 12 months and after at least 5 years. Logistic regression models were constructed to assess risk factors using total ENT and overall VDI score over the follow-up period, the proportion of patients with increased VDI score and the presence or absence of damage as the main outcomes. One hundred and thirty-eight patients were included. Ninety patients (65%) had long-term damage and 81% of these (73/90) developed some damage in the first 12 months. Positive ENT activity score (BVAS) at baseline and relapses were associated with higher ENT VDI scores long-term (OR = 6.90, 95% CI 2.01-23.75; OR = 2.65, 95% CI 1.20-5.82). Increasing BVAS score showed a trend towards lower VDI scores (OR = 0.93, 95% CI 0.88-0.99). Only ENT relapses and number of relapses were associated with an increase in VDI over time (OR = 8.38, 95% CI 3.10-22.68; OR = 1.79, 95% CI 1.24-2.58). In conclusion, most of the ENT damage in these patients was accrued within 12 months of diagnosis. We have shown an association between later ENT damage and the presence of ENT disease at baseline; lower initial BVAS and higher rate of disease relapse. © Springer-Verlag 2010

Entities:  

Mesh:

Year:  2010        PMID: 21085976     DOI: 10.1007/s00405-010-1421-x

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  25 in total

1.  Damage occurs early in systemic vasculitis and is an index of outcome.

Authors:  A R Exley; D M Carruthers; R A Luqmani; G D Kitas; C Gordon; B A Janssen; C O Savage; P A Bacon
Journal:  QJM       Date:  1997-06

2.  Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases.

Authors:  Steven B Cannady; Pete S Batra; Curry Koening; Robert R Lorenz; Martin J Citardi; Carol Langford; Gary S Hoffman
Journal:  Laryngoscope       Date:  2009-04       Impact factor: 3.325

3.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

4.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

5.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

6.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

7.  Hearing loss in Wegener's granulomatosis.

Authors:  Sivasanker Bakthavachalam; Mark S Driver; Clarke Cox; Jeffrey H Spiegel; Kenneth M Grundfast; Peter A Merkel
Journal:  Otol Neurotol       Date:  2004-09       Impact factor: 2.311

8.  The future of damage assessment in vasculitis.

Authors:  Philip Seo; Raashid A Luqmani; Oliver Flossmann; Bernhard Hellmich; Karen Herlyn; Gary S Hoffman; David Jayne; Cees G M Kallenberg; Carol A Langford; Alfred Mahr; Eric L Matteson; Chetan B Mukhtyar; Tuhina Neogi; Abraham Rutgers; Ulrich Specks; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

Review 9.  Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee.

Authors:  G Anderson; E T Coles; M Crane; A C Douglas; A R Gibbs; D M Geddes; E T Peel; J B Wood
Journal:  Q J Med       Date:  1992-06

10.  Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.

Authors:  John H Stone
Journal:  Arthritis Rheum       Date:  2003-08
View more
  2 in total

Review 1.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

Review 2.  Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis).

Authors:  Ruth M Tarzi; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2014-04-17       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.